Prosecution Insights
Last updated: April 19, 2026
Application No. 18/011,123

COMPOSITION FOR CONTROLLING SUGAR BEET CERCOSPORA LEAF SPOT DISEASE

Non-Final OA §102§103
Filed
Dec 16, 2022
Examiner
IVANOVA, SVETLANA M
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BAYER AKTIENGESELLSCHAFT
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
2y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allow Rate
417 granted / 828 resolved
-9.6% vs TC avg
Strong +51% interview lift
Without
With
+51.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
32 currently pending
Career history
860
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
41.9%
+1.9% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 828 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 2 and 4 are rejected under 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) as being anticipated by WO 2009074235 A1 to Assmann et al. (“Assmann”). Claim interpretation Claim 1 recites the limitation “[a] composition for controlling Cercospora leaf spot of beet”. The limitation “for controlling Cercospora leaf spot of beet” is interpreted as an intended use of a composition, which is not given any patentable weight. Rejection Assman relates to active compound combinations, in particular a fungicidal and/or insecticidal composition, comprising Isotianil (3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide, CAS No 224049-04-1) and and at least one further insecticide of the fiprole group and one further insecticide of the neonicotinoids. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops. (Abstract). Preferred preference is given to combinations comprising, e.g., compound (A) Isotianil and (B) ethiprole and (C) clothianidin. (p. 3, ll. 22-23). Per Applicant’s specification, para [0045], ethiprole is one of GABA-gated chloride channel blockers, and clothianidin is one of nicotinic acetylcholine receptor (nAChR) competitive modulators. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 5-8 and 12-15 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2009074235 A1 to Assmann et al. (“Assmann”). Assman relates to active compound combinations, in particular a fungicidal and/or insecticidal composition, comprising Isotianil (3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide, CAS No 224049-04-1) and at least one further insecticide of the fiprole group and one further insecticide of the neonicotinoids. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops. (Abstract). Preferred preference is given to combinations comprising, e.g., compound (A) Isotianil and (B) ethiprole and (C) clothianidin. (p. 3, ll. 22-23). Per Applicant’s specification, para [0045], ethiprole is one of GABA-gated chloride channel blockers, and clothianidin is one of nicotinic acetylcholine receptor (nAChR) competitive modulators. Per Assmann, among the plants that can be protected by the method according to the invention is beet (e.g. sugar beet, mangold and feed beet). (p. 33, ll. 2-3). Per Assmann, among the diseases of plants or crops that can be controlled by the method according to the invention, mention may be made of leafspot diseases such as Cercospora diseases caused for example by Cercospora beticola. Cercospora leaf spot and blight (Cercospora kikuchii), Frogeye Leaf spot (Cercospora sojina). (p. 37, ll. 26-28 et seq.). Per Assmann, it is also known that the combination of Isotianil with neonicotinoids is suitable for controlling phytopathogenic fungi (WO 2005/009131). (p. 1, ll. 26-27). Assmann discloses a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops comprising the use of a fungicide or insecticide composition according to the invention by application to the seed, the plant or to the fruit of the plant or to the soil in which the plant is growing or in which it is desired to grow. (p. 7, ll. 8-10). Per Assmann, in a very particular embodiment a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops is described comprising the use of the combination of (A) and (B) and (C) by application to the seed, plant propagation material, the plant or to the fruit of genetically modified plants. (p. 26, ll. 1-4). A person of skill in the art would understand application to plant propagation material to be inclusive of treating the seedbed for culturing the plant body. Assmann reports with reference to Table D-I, which includes data on testing of inventive compound combinations, to include on leaves, that “[t]he table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.” Per Assmann, “[t]he treatment of plants and plant parts with the active compound combination according to the invention is carried out directly or by action on their environment, habitat or storage area by means of the normal treatment methods.” (p. 29, ll. 30-31). A person of skill in the art would understand this disclosure to be inclusive of treating the seedbed for culturing the plant body. Per Assmann, “the substances according to the invention can be employed for protecting plants against attack by the abovementioned pathogens within a certain period of time after the treatment. The period of time within which protection is effected generally extends from 1 to 10 days, preferably 1 to 7 days, after the treatment of the plants with the active compounds.” (p. 26, ll. 16-19). Assmann discloses treating both soil and a plant body, but does not specifically disclose treating a soil for culturing the plant body with isotianil and at intervals of one more months treating the plant body with isotianil. However, where the general conditions are disclosed in the art, it would have been obvious to one of skill in the art before the effective filing date of the claimed invention to optimize the schedule of administration with a reasonable expectation of success. The skilled artisan would have been motivated to do so in order to optimize the therapeutic effect, with minimizing the decease burden while maintaining plant health at a safe dose. Claims 1-3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CN109068641A to Wetcholowsky et al. (“Wetcholwsky”). Claim interpretation Claim 1 recites the limitation “[a] composition for controlling Cercospora leaf spot of beet”. The limitation “for controlling Cercospora leaf spot of beet” is interpreted as an intended use of a composition, which is not given any patentable weight. Rejection Wetcholwsky discloses and claims a composition with a combination of: (A) at least one compound selected from following host defense inducers: isotianil, diazosulfide, probenazole and tiadinil, with (B) at least one Fungicidal active compound, be selected from following methoxy acrylate members: trifloxystrobin, dimoxystrobin, fluorine are phonetic Bacterium ester, pyraclostrobin, Enestroburin, ZEN 90160, Fluoxastrobin and Mandestrobin; And (C) another Fungicidal active compound Tebuconazole. This discloses specific additional compounds, per Applicant’s claims 3, in accordance with Applicant’s specification para [0044]. Per Wetcholwsky, composition according to the invention can be used for curatively or prophylactically controlling plant pathogenic fungi or plant or crop Bacterium. Therefore, according to another aspect of the present invention, a kind of plant for curatively or prophylactically controlling plant or crop is provided. The plant that can be protected include Chenopodiaceae (Chenopodiaceae sp.) (such as beet Root). Wetcholwsky further discloses as suitable plants for protection one with resistance to sulfonylureas and/or quinolone, such as soybean, rice, beet, lettuce or sunflower. Applicant can be for part of plant or plant, for example, stem, leaf, Stem tuber, seed, fruit. In the disease of controllable plant or crop by the method for the invention, it can be mentioned that: Particle spot, leaf spot, dirty leaf disease and leaf blight, such as Cercospora (Cerospora) disease, such as caused by beet raw tail spore (Cerospora beticola). Any inquiry concerning this communication or earlier communications from the examiner should be directed to SVETLANA M IVANOVA whose telephone number is (571)270-3277. The examiner can normally be reached 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney L. Klinkel can be reached at (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SVETLANA M IVANOVA/ Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Dec 16, 2022
Application Filed
Nov 26, 2025
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594248
STRESS MANAGEMENT IN HUMAN SUBJECTS IN NEED THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12595227
COMPOSITIONS AND METHODS FOR TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS
2y 5m to grant Granted Apr 07, 2026
Patent 12583850
SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12568970
IMPROVED STABILITY INSECTICIDAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
2y 5m to grant Granted Mar 10, 2026
Patent 12558336
METABOLIC RESCUE OF RETINAL DEGENERATION
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+51.3%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 828 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month